Point your AI agent at freehire and let it find you a job.

Get the CLI →

Disc Medicine

Develops treatments for patients with serious hematologic diseases.

H-1B sponsor history — This employer has had H-1B petitions approved by USCIS in the last five fiscal years, per the USCIS H-1B Employer Data Hub. The approval belongs to the employer and is not a commitment to sponsor this role.
Discussion

Company facts

Founded
2017
Employees
155
Headquarters
United States
CEO
John Quisel
Type
Public
Listed
NASDAQ: IRON

About

Disc Medicine is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. The company is building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. With a focused approach on hematology, Disc Medicine is advancing multiple clinical programs targeting rare genetic disorders and common anemias of chronic disease. Their pipeline includes Bitopertin, an orally administered GlyT1 inhibitor for erythropoietic protoporphyrias; DISC-0974, an anti-HJV monoclonal antibody for hepcidin suppression in anemia; and DISC-3405, an anti-TMPRSS6 antibody for hepcidin induction. The company operates from its headquarters in Watertown, Massachusetts, and is publicly traded on NASDAQ under the ticker IRON.

3 jobs

Tailor your CV for this role?

We couldn't check your fit for this role — add a CV to your profile to see it next time.

A new version of freehire is available